TRPM7

Summary

TRPM7 (transient receptor potential cation channel subfamily M member 7, HGNC:17994) is a protein-coding gene on chromosome 15q21.2, encoding Transient receptor potential cation channel subfamily M member 7 (Q96QT4). Bifunctional protein that combines an ion channel with an intrinsic kinase domain, enabling it to modulate cellular functions either by conducting ions through the pore or by phosphorylating downstream proteins via its kinase domain. It is a selective cancer dependency (DepMap: 62.2% of cell lines).

This gene belongs to the melastatin subfamily of transient receptor potential family of ion channels. The protein encoded by this gene is both an ion channel and a serine/threonine protein kinase. The kinase activity is essential for the ion channel function, which serves to increase intracellular calcium levels and to help regulate magnesium ion homeostasis. The encoded protein is involved in cytoskeletal organization, cell adhesion, cell migration and organogenesis. Defects in this gene are a cause of amyotrophic lateral sclerosis-parkinsonism/dementia complex of Guam. The gene may also be associated with defects of cardiac function.

Source: NCBI Gene 54822 — RefSeq curated summary.

At a glance

• Gene–disease (curated): familial primary hypomagnesemia (Strong, GenCC) — +5 more curated relationships
• GWAS associations: 13
• Clinical variants (ClinVar): 326 total — 3 pathogenic
• Phenotypes (HPO): 21
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 62.2% of screened cell lines
• MANE Select transcript: NM_017672

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17994
Approved symbol	TRPM7
Name	transient receptor potential cation channel subfamily M member 7
Location	15q21.2
Locus type	gene with protein product
Status	Approved
Aliases	CHAK1, LTRPC7, TRP-PLIK
Ensembl gene	ENSG00000092439
Ensembl biotype	protein_coding
OMIM	605692
Entrez	54822

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 5 retained_intron, 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000558444, ENST00000560284, ENST00000560516, ENST00000560638, ENST00000560849, ENST00000560955, ENST00000561267, ENST00000561443, ENST00000645282, ENST00000646667

RefSeq mRNA: 2 — MANE Select: NM_017672 NM_001301212, NM_017672

CCDS: CCDS42035, CCDS73725

Canonical transcript exons

ENST00000646667 — 39 exons

Exon	Start	End
ENSE00000884659	50614123	50614263
ENSE00000884661	50619745	50619798
ENSE00000884663	50624166	50624300
ENSE00000884665	50628149	50628249
ENSE00000884666	50631417	50631489
ENSE00000884669	50632869	50632992
ENSE00000884670	50634382	50634556
ENSE00000884674	50639424	50639548
ENSE00000884675	50643340	50643553
ENSE00000884677	50648687	50648885
ENSE00000884679	50657781	50657819
ENSE00000942189	50637422	50637593
ENSE00000942190	50613707	50613841
ENSE00001015026	50607200	50607328
ENSE00001015028	50593617	50593749
ENSE00001015029	50609806	50609961
ENSE00001015031	50609581	50609724
ENSE00001015035	50583089	50583159
ENSE00001015037	50604866	50605144
ENSE00001015039	50599122	50599296
ENSE00001015041	50589592	50589656
ENSE00001015042	50591911	50592626
ENSE00001015048	50611093	50611321
ENSE00001015052	50612549	50612829
ENSE00001015056	50586392	50586488
ENSE00001316070	50662967	50663046
ENSE00002573869	50557158	50561808
ENSE00003460516	50574637	50574719
ENSE00003461129	50596255	50596381
ENSE00003490803	50575869	50575919
ENSE00003525258	50574852	50575135
ENSE00003536554	50570104	50570155
ENSE00003543849	50575724	50575789
ENSE00003559439	50574274	50574479
ENSE00003559788	50580874	50580908
ENSE00003564664	50569887	50569993
ENSE00003566028	50594429	50594613
ENSE00003640191	50578639	50578664
ENSE00003814321	50686531	50686797

Expression profiles

Bgee: expression breadth ubiquitous, 247 present calls, max score 96.15.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 18.1925 / max 187.9243, expressed in 1805 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
149872	13.4469	1793
149871	4.7456	1587

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	96.15	gold quality
calcaneal tendon	UBERON:0003701	95.45	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.35	gold quality
adrenal tissue	UBERON:0018303	91.74	gold quality
colonic epithelium	UBERON:0000397	91.56	gold quality
sural nerve	UBERON:0015488	91.33	gold quality
tendon	UBERON:0000043	91.17	gold quality
cartilage tissue	UBERON:0002418	90.13	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	89.70	gold quality
myocardium	UBERON:0002349	89.45	gold quality
mucosa of stomach	UBERON:0001199	88.80	gold quality
right lobe of liver	UBERON:0001114	88.70	gold quality
buccal mucosa cell	CL:0002336	88.55	silver quality
stromal cell of endometrium	CL:0002255	88.49	gold quality
bone marrow cell	CL:0002092	88.20	gold quality
islet of Langerhans	UBERON:0000006	88.19	gold quality
monocyte	CL:0000576	87.91	gold quality
leukocyte	CL:0000738	87.77	gold quality
kidney epithelium	UBERON:0004819	87.49	gold quality
rectum	UBERON:0001052	87.34	gold quality
liver	UBERON:0002107	87.34	gold quality
left ovary	UBERON:0002119	87.31	gold quality
heart left ventricle	UBERON:0002084	86.83	gold quality
vermiform appendix	UBERON:0001154	86.75	gold quality
right ovary	UBERON:0002118	86.72	gold quality
ovary	UBERON:0000992	86.69	gold quality
cardiac ventricle	UBERON:0002082	86.68	gold quality
smooth muscle tissue	UBERON:0001135	86.63	gold quality
cortex of kidney	UBERON:0001225	86.50	gold quality
cerebellar hemisphere	UBERON:0002245	86.30	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-131882	yes	3492.00
E-CURD-119	yes	3271.27
E-ANND-3	yes	5.90
E-MTAB-7606	no	127.48

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

161 targeting TRPM7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-5696	99.98	72.36	4487

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 62.2% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 40)

• only Mg(2+) can directly modulate TRPM7/ChaK1 kinase activity in vivo (PMID:14594813)
• TRPM7 activity is up- and down-regulated through its endogenous kinase in a cAMP- and protein kinase A-dependent manner (PMID:15069188)
• TRPM7 is a functionally important regulator of Mg2+ homeostasis and growth in vascular smooth muscle cells. (PMID:15591230)
• A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders. (PMID:16051700)
• TRPM7-deficient cells become Mg(2+) deficient & are not viable.TRPM7 is characterized functionally as constitutively active ion channel permeable for variety of cations including Ca & Mg & regulated by intracellular Mg &/or Mg-nucleotide complexes[review] (PMID:16075242)
• Although TRPM6 and TRPM7 are closely related and deficiency in either one of these molecules severely affects Mg(2+) homeostasis regulation, TRPM6 and TRPM7 do not appear to be functionally redundant. (PMID:16150690)
• Both endogenous and heterologously expressed TRPM7 was found in tubulovesicular structures that were translocated to the region of the plasma membrane on induction of shear stress. (PMID:16357306)
• Regulation of cell adhesion by TRPM7 is the combined effect of kinase-dependent and -independent pathways on actomyosin contractility. (PMID:16407977)
• the ion channel TRPM7 regulates cell adhesion through m-calpain by mediating the local influx of calcium into peripheral adhesion complexes (PMID:16436382)
• We conclude that the nucleotide-dependent regulation of TRPM7 is mediated by the nucleotide binding site on the channel’s endogenous kinase domain and interacts synergistically with a Mg(2+) binding site extrinsic to that domain. (PMID:16533898)
• heterologous expression of TRPM6 but not the mutant TRPM6(S141L) produces functional channels with divalent cation permeability profile and pH sensitivity distinctive from those of TRPM7 channels and TRPM6/7 complexes (PMID:16636202)
• TRPM7 is stretch- and swelling-activated cation channel endogenously expressed in HeLa cells. By serving as swelling-induced Ca(2+) influx pathway, it has important role in cell volume regulation. (PMID:16943238)
• under physiological ionic conditions, TRPM7 currents are activated rather than inhibited by PLC-activating receptor agonists (PMID:17095511)
• the channel may serve as a regulated transport mechanism for these ions that could affect cell adhesion, cell growth and proliferation, and even cell death under pathological stress such as anoxia–{REVIEW} (PMID:17217066)
• We thus conclude that the TRPM7 channel can be directly activated by mechano-stress in a manner independent of exocytosis-mediated incorporation of this channel protein into the plasma membrane. (PMID:17310095)
• TRPM7 senses osmotically induced changes primarily through molecular crowding of solutes that affect channel activity. (PMID:17510191)
• The inner membrane potential (as regulated by proton ionophores) and the F1/FO-ATP synthase of mitochondria are important in regulating TRPM7 channels. (PMID:17646711)
• Human mast cells express functional TRPM7 channels that are a critical requirement for cell survival. (PMID:17785843)
• The subjects who carried >or=1 1482Ile allele and who consumed diets with a high Ca:Mg intake were at a higher risk of adenoma and hyperplastic polyps than were the subjects who did not carry the polymorphism (PMID:17823441)
• Transient receptor potential melastatin 7-like current has a role in cell proliferation in human head and neck carcinoma cells (PMID:18006838)
• restoration of only two “ancient” pore residues in human TRPM2 (Q981E/P983Y) significantly increased (approximately 4-fold) its permeability for Ca(2+). (PMID:18073331)
• This review discusses the importance of magnesium in vascular biology and implications in hypertension and highlights the transport systems, particularly TRPM7–REVIEW (PMID:18192217)
• The predominant Mg transporters include TRPM6 and TRPM7 (PMID:18301276)
• findings support a model where massive autophosphorylation outside the catalytic domain of TRPM6 and TRPM7 may facilitate kinase-substrate interactions leading to enhanced phosphorylation of those substrates (PMID:18365021)
• proton conductivity of endogenous human TRPM7 plays a role in physiologically/pathologically acidic situations. (PMID:18390554)
• TRPM6 and TRPM7 phosphorylate the assembly domain of myosin IIA, IIB and IIC on identical residues. (PMID:18675813)
• in human TRPM7, both Asp-1054 and Glu-1052, may provide binding sites for Mg(2+) and Ca(2+); Asp-1054 is an essential determinant of Mg(2+)and Ca(2+) conductivity; Glu-1052 and Asp-1059 facilitate conduction of divalent cations (PMID:18719395)
• TRPM7 is present in human head and neck squamous carcinoma cells. siRNA silencing of TRPM7 inhibited the growth and proliferation of these cells. (PMID:18826101)
• Suppression of TRPM7 induces cell death in gastric cancer. (PMID:19032368)
• bradykinin regulates TRPM7 and its downstream target annexin-1 through phospholipase C-dependent, protein kinase C-dependent and c-Src-dependent and cAMP-independent pathways. (PMID:19145781)
• there was no evidence of association between common TRPM7 haplotypes and diabetes risk (PMID:19149903)
• results indicate that TRPM7 is not associated with ALS/PDC in the Kii peninsula of Japan (PMID:19405049)
• Silencing TRPM7 promotes growth/proliferation and nitric oxide production of vascular endothelial cells via the ERK pathway. (PMID:19454490)
• These findings strongly suggest that TRPM7 is involved in the proliferative potentiality of breast cancer cells, probably by regulating Ca(2+) influx. (PMID:19515901)
• no evidence of a role for the TRPM7 gene in the risk of incident ischemic stroke. (PMID:19644062)
• These results suggest that the human GI tract generates slow waves and that TRPM7 channels expressed in the interstitial cells of Cajal may be involved in the generation of the slow waves. (PMID:19998500)
• excessive TRPM7 channel activity causes oxidative and nitrosative stresses, producing cell rounding mediated by p38 MAPK/JNK-dependent activation of m-calpain (PMID:20070945)
• Results establish that TRPM7 is the major Ca(2+)-permeable channel in human atrial fibroblasts and likely plays an essential role in TGF-beta1-elicited fibrogenesis in human atrial fibrillation. (PMID:20075334)
• The present investigation further suggests that TRPM6 and TRPM7 gene variation may not be useful predictors for type 2 diabetes mellitus risk assessment. (PMID:20875900)
• TRPM7’s structural duality ensures ideal positioning of its kinase in close proximity to channel-mediated Mg(2+) uptake, allowing for the adjustment of protein translational rates to the availability of Mg(2+). (PMID:21112387)

Cross-species orthologs

9 orthologs

Organism	Symbol	Gene ID
danio_rerio	trpm7	ENSDARG00000036232
mus_musculus	Trpm7	ENSMUSG00000027365
rattus_norvegicus	Trpm7	ENSRNOG00000057806
drosophila_melanogaster	Trpm	FBGN0265194
caenorhabditis_elegans	gon-2	WBGENE00001651
caenorhabditis_elegans		WBGENE00004149
caenorhabditis_elegans		WBGENE00020972
caenorhabditis_elegans		WBGENE00021404
caenorhabditis_elegans		WBGENE00021408

Paralogs (7): TRPM5 (ENSG00000070985), TRPM3 (ENSG00000083067), TRPM6 (ENSG00000119121), TRPM4 (ENSG00000130529), TRPM1 (ENSG00000134160), TRPM2 (ENSG00000142185), TRPM8 (ENSG00000144481)

Protein

Protein identifiers

Transient receptor potential cation channel subfamily M member 7 — Q96QT4 (reviewed: Q96QT4)

Alternative names: Channel-kinase 1, Long transient receptor potential channel 7

All UniProt accessions (4): Q96QT4, A0A0C4DGL2, H0YLN8, H0YNM0

UniProt curated annotations — full annotation on UniProt →

Function. Bifunctional protein that combines an ion channel with an intrinsic kinase domain, enabling it to modulate cellular functions either by conducting ions through the pore or by phosphorylating downstream proteins via its kinase domain. The channel is highly permeable to divalent cations, specifically calcium (Ca2+), magnesium (Mg2+) and zinc (Zn2+) and mediates their influx. Controls a wide range of biological processes such as Ca2(+), Mg(2+) and Zn(2+) homeostasis, vesicular Zn(2+) release channel and intracellular Ca(2+) signaling, embryonic development, immune responses, cell motility, proliferation and differentiation. The C-terminal alpha-kinase domain autophosphorylates cytoplasmic residues of TRPM7. In vivo, TRPM7 phosphorylates SMAD2, suggesting that TRPM7 kinase may play a role in activating SMAD signaling pathways. In vitro, TRPM7 kinase phosphorylates ANXA1 (annexin A1), myosin II isoforms and a variety of proteins with diverse cellular functions. The cleaved channel exhibits substantially higher current and potentiates Fas receptor signaling. The C-terminal kinase domain can be cleaved from the channel segment in a cell-type-specific fashion. In immune cells, the TRPM7 kinase domain is clipped from the channel domain by caspases in response to Fas-receptor stimulation. The cleaved kinase fragments can translocate to the nucleus, and bind chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to ultimately phosphorylate specific Ser/Thr residues of histones known to be functionally important for cell differentiation and embryonic development.

Subunit / interactions. Homotetramer. Interacts with PLCB1. Forms heteromers with TRPM6; heteromeric channels are functionally different from the homomeric channels.

Subcellular location. Cell membrane. Cytoplasmic vesicle membrane Nucleus.

Post-translational modifications. Palmitoylated; palmitoylation at Cys-1143, Cys-1144 and Cys-1146 promotes TRPM7 trafficking from the Golgi to the surface membrane. Autophosphorylated; autophosphorylation of C-terminus regulates TRPM7 kinase activity towards its substrates. The C-terminal kinase domain can be cleaved from the channel segment in a cell-type-specific fashion. TRPM7 is cleaved by caspase-8, dissociating the kinase from the ion-conducting pore. The cleaved kinase fragments (M7CKs) can translocate to the cell nucleus and binds chromatin-remodeling complex proteins in a Zn(2+)-dependent manner to ultimately phosphorylate specific Ser/Thr residues of histones.

Disease relevance. Amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 (ALS-PDC1) [MIM:105500] A neurodegenerative disorder characterized by chronic, progressive and uniformly fatal amyotrophic lateral sclerosis and parkinsonism-dementia. Both diseases are known to occur in the same kindred, the same sibship and even the same individual. Disease susceptibility is associated with variants affecting the gene represented in this entry. TRPM7 variants have been identified as a potential cause of disease in patients suffering from seizures and muscle cramps due to magnesium deficiency and episodes of hypocalcemia.

Activity regulation. Channel displays constitutive activity. Channel activity is negatively regulated by cytosolic Mg(2+) and Mg-ATP. Channel activity is negatively regulated by low intracellular pH. Resting free cytosolic Mg(2+) and Mg-ATP concentrations seem to be sufficient to block native TRPM7 channel activity. TRPM7 channel activity is highly dependent on membrane levels of phosphatidylinositol 4,5 bisphosphate (PIP2). PIP2 hydrolysis negatively regulates TRPM7 channel activity. TRPM7 kinase activity does not affect channel activity. The kinase activity is controlled through the autophosphorylation of a serine/threonine-rich region located N-terminal to the catalytic domain.

Cofactor. Binds 1 zinc ion per subunit.

Similarity. In the C-terminal section; belongs to the protein kinase superfamily. Alpha-type protein kinase family. ALPK subfamily. In the N-terminal section; belongs to the transient receptor (TC 1.A.4) family. LTrpC subfamily. TRPM7 sub-subfamily.

RefSeq proteins (2): NP_001288141, NP_060142* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004166	a-kinase_dom	Domain
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR029601	TRPM7_a-kinase_dom	Domain
IPR032415	TRPM_tetra	Domain
IPR037162	TRPM_tetra_sf	Homologous_superfamily
IPR041491	TRPM_SLOG	Domain
IPR050927	TRPM	Family
IPR057366	TRPM-like	Domain

Pfam: PF02816, PF16519, PF18139, PF25508

Catalyzed reactions (Rhea), 5 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• Zn(2+)(in) = Zn(2+)(out) (RHEA:29351)
• Ca(2+)(in) = Ca(2+)(out) (RHEA:29671)
• Mg(2+)(in) = Mg(2+)(out) (RHEA:29827)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (123 total): modified residue 54, sequence variant 16, binding site 13, topological domain 8, transmembrane region 6, region of interest 5, compositionally biased region 5, sequence conflict 4, chain 3, lipid moiety-binding region 3, mutagenesis site 2, intramembrane region 1, domain 1, coiled-coil region 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96QT4-F1	69.90	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 1767 (proton acceptor)

Ligand- & substrate-binding residues (13): 1621; 1622; 1623; 1624; 1648; 1720; 1721; 1723; 1753; 1777; 1810; 1812 …

Post-translational modifications (57): 1146, 1, 101, 1163, 1191, 1193, 1224, 1255, 1258, 1265, 1287, 1301, 1358, 1361, 1386, 1387, 1390, 1395, 1396, 1404 …

Mutagenesis-validated functional residues (2):

Position	Phenotype
1648	loss of kinase activity.
1799	loss of kinase activity.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-3295583	TRP channels

MSigDB gene sets: 214 (showing top): GOBP_PROTEIN_HOMOTETRAMERIZATION, NKX25_02, GOBP_TRANSITION_METAL_ION_TRANSPORT, AAGCCAT_MIR135A_MIR135B, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, AREB6_01, GOCC_RUFFLE, GOBP_MAGNESIUM_ION_TRANSPORT, GOBP_MONOATOMIC_CATION_TRANSPORT, GOBP_ACTOMYOSIN_STRUCTURE_ORGANIZATION, CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN, DODD_NASOPHARYNGEAL_CARCINOMA_UP, TGTTTAC_MIR30A5P_MIR30C_MIR30D_MIR30B_MIR30E5P, GOBP_MONOATOMIC_ION_HOMEOSTASIS, GOMF_ACTIN_BINDING

GO Biological Process (20): protein phosphorylation (GO:0006468), calcium ion transport (GO:0006816), zinc ion transport (GO:0006829), magnesium ion homeostasis (GO:0010960), intracellular magnesium ion homeostasis (GO:0010961), magnesium ion transport (GO:0015693), calcium-dependent cell-matrix adhesion (GO:0016340), actomyosin structure organization (GO:0031032), protein autophosphorylation (GO:0046777), protein homotetramerization (GO:0051289), necroptotic process (GO:0070266), calcium ion transmembrane transport (GO:0070588), monoatomic cation transmembrane transport (GO:0098655), monoatomic ion transport (GO:0006811), programmed cell death (GO:0012501), monoatomic ion transmembrane transport (GO:0034220), protein tetramerization (GO:0051262), transmembrane transport (GO:0055085), zinc ion transmembrane transport (GO:0071577), magnesium ion transmembrane transport (GO:1903830)

GO Molecular Function (16): actin binding (GO:0003779), protein kinase activity (GO:0004672), protein serine/threonine kinase activity (GO:0004674), calcium channel activity (GO:0005262), zinc ion transmembrane transporter activity (GO:0005385), ATP binding (GO:0005524), magnesium ion transmembrane transporter activity (GO:0015095), myosin binding (GO:0017022), metal ion binding (GO:0046872), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), monoatomic ion channel activity (GO:0005216), monoatomic cation channel activity (GO:0005261), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (6): ruffle (GO:0001726), nucleus (GO:0005634), plasma membrane (GO:0005886), cytoplasmic vesicle membrane (GO:0030659), cytoplasmic vesicle (GO:0031410), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Stimuli-sensing channels	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
monoatomic cation transmembrane transport	3
metal ion transport	2
transport	2
cytoskeletal protein binding	2
protein kinase activity	2
phosphorylation	1
protein modification process	1
transition metal ion transport	1
monoatomic cation homeostasis	1
inorganic ion homeostasis	1
magnesium ion homeostasis	1
intracellular monoatomic cation homeostasis	1
cell-matrix adhesion	1
actin cytoskeleton organization	1
protein phosphorylation	1
protein homooligomerization	1
protein tetramerization	1
programmed necrotic cell death	1
calcium ion transport	1
monoatomic cation transport	1
monoatomic ion transmembrane transport	1
signal transduction	1
cell death	1
monoatomic ion transport	1
transmembrane transport	1
protein complex oligomerization	1
cellular process	1
zinc ion transport	1
magnesium ion transport	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
monoatomic cation channel activity	1
calcium ion transmembrane transporter activity	1
transition metal ion transmembrane transporter activity	1
zinc ion transmembrane transport	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
metal ion transmembrane transporter activity	1
magnesium ion transmembrane transport	1

Protein interactions and networks

STRING

1760 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRPM7	TRPC1	P48995	808
TRPM7	TRPV2	Q9Y5S1	791
TRPM7	SLC41A1	Q8IVJ1	781
TRPM7	TRPA1	O75762	751
TRPM7	TRPV4	Q9HBA0	751
TRPM7	TRPV6	Q9H1D0	743
TRPM7	TRPV1	Q8NER1	742
TRPM7	TRPM6	Q9BX84	741
TRPM7	SLC41A2	Q96JW4	737
TRPM7	TRPV3	Q8NET8	726
TRPM7	TRPV5	Q9NQA5	720
TRPM7	PLCB1	Q9NQ66	714
TRPM7	SLC41A3	Q96GZ6	679
TRPM7	MAGT1	Q9H0U3	675
TRPM7	STIM1	Q13586	657

IntAct

56 interactions, top by confidence:

A	B	Type	Score
NEURL4	APBB1	psi-mi:“MI:0914”(association)	0.530
ZACN	GPAA1	psi-mi:“MI:0914”(association)	0.530
ARL15	SLC25A20	psi-mi:“MI:0914”(association)	0.530
PTP4A1	ATE1	psi-mi:“MI:0914”(association)	0.530
PKD2L2	PKD2	psi-mi:“MI:0914”(association)	0.530
TRPM7	MYH9	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
TRPM7	MYH10	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
TRPM7	MYH14	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
TRPM7	RPL27	psi-mi:“MI:0915”(physical association)	0.400
GPC1	SNAP23	psi-mi:“MI:0915”(physical association)	0.400
GPC1	GANAB	psi-mi:“MI:0915”(physical association)	0.400
K8.1	EXOC5	psi-mi:“MI:0914”(association)	0.350
NEURL4	CCDC85C	psi-mi:“MI:0914”(association)	0.350
TEX28	NBAS	psi-mi:“MI:0914”(association)	0.350
SNAP29	RNF40	psi-mi:“MI:0914”(association)	0.350
PNLDC1	C1QL1	psi-mi:“MI:0914”(association)	0.350
TTMP	TMEM223	psi-mi:“MI:0914”(association)	0.350
TTYH1	TMEM223	psi-mi:“MI:0914”(association)	0.350
ZACN	FAM234B	psi-mi:“MI:0914”(association)	0.350
PSCA	METTL15	psi-mi:“MI:0914”(association)	0.350
NKAIN1	GPR89A	psi-mi:“MI:0914”(association)	0.350
RABEP2	HECTD4	psi-mi:“MI:0914”(association)	0.350
EIF2B5	GOLIM4	psi-mi:“MI:0914”(association)	0.350
RYK	TNFRSF10B	psi-mi:“MI:0914”(association)	0.350
CD3D	CLGN	psi-mi:“MI:0914”(association)	0.350
CCDC107	TMEM131L	psi-mi:“MI:0914”(association)	0.350

BioGRID (179): TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Proximity Label-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS), TRPM7 (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IMY7, A0JPA0, A2AP18, A8DYE2, J9SQF3, O00329, O35904, O75038, P0C1Q3, P0C588, P19687, P33402, P48736, P97557, Q02108, Q09M05, Q148L1, Q1LWG4, Q2TV84, Q2WEA5, Q3USB7, Q4ZHS0, Q502J0, Q5EBA1, Q60565, Q62688, Q69ZF7, Q6P4Q7, Q6PA06, Q7L5N7, Q7TN37, Q7Z2W7, Q7Z4N2, Q80YD1, Q8BTI9, Q8BYI6, Q8BZN2, Q8CIR4, Q8NHH9, Q8R455

Diamond homologs: A0A0R4IMY7, A7T1N0, A8DYE2, E9PTA2, J9SQF3, O94759, Q09297, Q2TV84, Q2WEA5, Q5XIG0, Q7TN37, Q7Z2W7, Q7Z4N2, Q8BVU5, Q8CIR4, Q8R455, Q8R4D5, Q8TD43, Q91YD4, Q923J1, Q925B3, Q96QT4, Q9BW91, Q9BX84, Q9ESQ5, Q9HCF6, S5UH55, Q93971, O00418, O01991, O08796, P42527, P70531, P90648, Q54DK4, Q54SF9, Q6B9X6, Q8MY12, Q9CXB8, Q9JJH7

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
TRPM7	up-regulates	ANXA1	phosphorylation
TRPM7	“up-regulates activity”	EEF2K	phosphorylation
TRPM7	“up-regulates activity”	PLCG2	phosphorylation
TRPM6	“down-regulates quantity”	TRPM7	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 78 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	7	113.4×	6e-12
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	7	100.0×	1e-11
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	7	100.0×	1e-11
Activation of BH3-only proteins	7	74.0×	1e-10
RHO GTPases activate PKNs	10	67.5×	4e-14
Intrinsic Pathway for Apoptosis	7	43.6×	5e-09
Translocation of SLC2A4 (GLUT4) to the plasma membrane	11	36.1×	9e-13
FOXO-mediated transcription	5	35.7×	3e-06

GO biological processes:

GO term	Partners	Fold	FDR
protein targeting	5	27.8×	2e-04
intracellular protein localization	8	12.7×	1e-04
exocytosis	5	11.5×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

326 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	213
Likely benign	21
Benign	34

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
2664953	NM_017672.6(TRPM7):c.2999T>C (p.Met1000Thr)	Pathogenic
2664954	NM_017672.6(TRPM7):c.3242T>G (p.Leu1081Arg)	Pathogenic
974783	NM_017672.6(TRPM7):c.3137G>A (p.Gly1046Asp)	Pathogenic

SpliceAI

6192 predictions. Top by Δscore:

Variant	Effect	Δscore
15:50570162:A:C	acceptor_gain	1.0000
15:50570164:G:C	acceptor_gain	1.0000
15:50570164:G:GC	acceptor_gain	1.0000
15:50570166:G:C	acceptor_gain	1.0000
15:50570166:G:GC	acceptor_gain	1.0000
15:50570168:A:C	acceptor_gain	1.0000
15:50570170:A:C	acceptor_gain	1.0000
15:50574298:C:CA	donor_gain	1.0000
15:50574299:C:A	donor_gain	1.0000
15:50574481:T:C	acceptor_gain	1.0000
15:50574850:A:AC	donor_gain	1.0000
15:50574851:C:CC	donor_gain	1.0000
15:50574851:CT:C	donor_gain	1.0000
15:50574851:CTCT:C	donor_gain	1.0000
15:50575787:CAG:C	acceptor_gain	1.0000
15:50575790:C:CC	acceptor_gain	1.0000
15:50575794:A:C	acceptor_gain	1.0000
15:50586489:C:CC	acceptor_gain	1.0000
15:50589584:TTAC:T	donor_loss	1.0000
15:50589585:TAC:T	donor_loss	1.0000
15:50589586:AC:A	donor_loss	1.0000
15:50589588:TTACG:T	donor_loss	1.0000
15:50589589:T:TG	donor_loss	1.0000
15:50589590:A:AC	donor_gain	1.0000
15:50589590:A:C	donor_loss	1.0000
15:50589591:C:CA	donor_loss	1.0000
15:50589591:C:CT	donor_gain	1.0000
15:50589591:CG:C	donor_gain	1.0000
15:50589591:CGG:C	donor_gain	1.0000
15:50589591:CGGA:C	donor_gain	1.0000

AlphaMissense

12379 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
15:50574436:A:G	W1716R	1.000
15:50574436:A:T	W1716R	1.000
15:50592522:A:G	L1238P	1.000
15:50593706:A:C	F1173L	1.000
15:50593706:A:T	F1173L	1.000
15:50593707:A:G	F1173S	1.000
15:50593708:A:G	F1173L	1.000
15:50593716:A:G	L1170P	1.000
15:50594571:C:A	W1111C	1.000
15:50594571:C:G	W1111C	1.000
15:50594573:A:G	W1111R	1.000
15:50594573:A:T	W1111R	1.000
15:50596270:A:G	L1092P	1.000
15:50596270:A:T	L1092H	1.000
15:50596273:A:G	L1091P	1.000
15:50596275:A:C	N1090K	1.000
15:50596275:A:T	N1090K	1.000
15:50596303:A:G	L1081P	1.000
15:50599148:C:A	G1046V	1.000
15:50599149:C:A	G1046C	1.000
15:50599149:C:G	G1046R	1.000
15:50599175:A:T	V1037D	1.000
15:50599241:C:T	G1015D	1.000
15:50599242:C:G	G1015R	1.000
15:50599246:A:C	S1013R	1.000
15:50599246:A:T	S1013R	1.000
15:50599248:T:G	S1013R	1.000
15:50599265:A:C	M1007R	1.000
15:50599265:A:T	M1007K	1.000
15:50604895:C:G	G987R	1.000

dbSNP variants (sampled 300 via entrez): RS1000038635 (15:50616468 C>T), RS1000057210 (15:50677707 C>A), RS1000066824 (15:50577557 C>T), RS1000080903 (15:50641107 G>A), RS1000100744 (15:50602873 G>A), RS1000106757 (15:50569595 C>T), RS1000134546 (15:50654314 G>T), RS1000160383 (15:50608503 T>C), RS1000168810 (15:50581955 T>C,G), RS1000179886 (15:50611727 A>T), RS1000180877 (15:50579581 T>TA), RS1000187615 (15:50647113 C>T), RS1000211793 (15:50608059 AAAAAAAAAAAAG>A), RS1000221819 (15:50621302 G>A,T), RS1000230665 (15:50572865 A>G)

Disease associations

OMIM: gene MIM:605692 | disease phenotypes: MIM:105500, MIM:602014

GenCC curated gene-disease

Disease	Classification	Inheritance
familial primary hypomagnesemia	Strong	Autosomal dominant
hypomagnesemia, seizures, and intellectual disability	Moderate	Autosomal dominant
sudden arrhythmia death syndrome	Moderate	Autosomal dominant
autosomal dominant macrothrombocytopenia	Supportive	Autosomal dominant
macrothrombocytopenia, isolated	Limited	Autosomal dominant
amyotrophic lateral sclerosis-parkinsonism-dementia complex	Limited	Unknown

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
macrothrombocytopenia, isolated	Moderate	AD

Mondo (8): amyotrophic lateral sclerosis-parkinsonism-dementia complex (MONDO:0007104), juvenile amyotrophic lateral sclerosis (MONDO:0017593), intestinal hypomagnesemia 1 (MONDO:0011176), hypomagnesemia, seizures, and intellectual disability (MONDO:0014631), macrothrombocytopenia, isolated (MONDO:0031447), autosomal dominant macrothrombocytopenia (MONDO:0015372), familial primary hypomagnesemia (MONDO:0018100), sudden arrhythmia death syndrome (MONDO:0054866)

Orphanet (3): Parkinson-dementia complex of Guam (Orphanet:90020), Juvenile amyotrophic lateral sclerosis (Orphanet:300605), Primary hypomagnesemia with secondary hypocalcemia (Orphanet:30924)

HPO phenotypes

21 total (21 of 21 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000421	Epistaxis
HP:0000726	Dementia
HP:0000978	Bruising susceptibility
HP:0001283	Bulbar palsy
HP:0001300	Parkinsonism
HP:0001324	Muscle weakness
HP:0001873	Thrombocytopenia
HP:0002059	Cerebral atrophy
HP:0002366	Abnormal lower motor neuron morphology
HP:0003394	Muscle spasm
HP:0003470	Paralysis
HP:0003584	Late onset
HP:0003596	Middle age onset
HP:0004846	Prolonged bleeding after surgery
HP:0006298	Prolonged bleeding after dental extraction
HP:0007354	Amyotrophic lateral sclerosis
HP:0011877	Increased mean platelet volume
HP:0032438	Platelet anisocytosis
HP:0040185	Macrothrombocytopenia
HP:0100608	Metrorrhagia

GWAS associations

13 associations (top):

Study	Trait	p-value
GCST002500_74	QT interval	3.000000e-12
GCST005982_8	Calcium levels	3.000000e-12
GCST007096_123	Pulse pressure	1.000000e-09
GCST007097_80	Pulse pressure	3.000000e-06
GCST007099_166	Systolic blood pressure	6.000000e-07
GCST007692_33	Chronic obstructive pulmonary disease	9.000000e-07
GCST009524_95	Household income (MTAG)	2.000000e-08
GCST011010_63	Electrocardiographic traits (multivariate)	2.000000e-06
GCST012676_6	Body composition traits	5.000000e-06
GCST012676_7	Body composition traits	6.000000e-08
GCST012676_8	Body composition traits	1.000000e-08
GCST90013663_56	Alanine aminotransferase levels	1.000000e-08
GCST90013664_86	Aspartate aminotransferase levels	5.000000e-12

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004682	QT interval
EFO:0004838	calcium measurement
EFO:0005763	pulse pressure measurement
EFO:0006335	systolic blood pressure
EFO:0009695	household income
EFO:0004327	electrocardiography
EFO:0004340	body mass index
EFO:0004736	aspartate aminotransferase measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
C566593	Hypomagnesemia 1, Intestinal (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1250412 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — ChaK subfamily

Most potent curated ligand interactions (9 total), top 9:

Ligand	Action	Affinity	Parameter
sphingosine	Inhibition	6.23	pIC50
fingolimod	Inhibition	6.14	pIC50
NS8593	Inhibition	5.8	pIC50
spermine	Inhibition	5.64	pKi
waixenicin A	Inhibition	5.15	pIC50
H+	Potentiation	4.5	pEC50
carvacrol	Inhibition	3.52	pIC50
nafamostat	Inhibition	3.21	pIC50
Mg2+	Antagonist	2.49	pIC50

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.05	IC50	90	nM	CHEMBL5423236
5.57	IC50	2700	nM	CANNABIGEROLIC ACID

PubChem BioAssay actives

2 with measured affinity, of 25 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(E,5S)-5-[(1R,4aS,7E,10R,11aR)-1-acetyloxy-10-hydroxy-7-methyl-11-methylidene-4a,5,6,9,10,11a-hexahydro-1H-cyclonona[c]pyran-4-yl]-5-acetyloxy-2-methylpent-2-enyl] acetate	2035477: Inhibition of human TRPM7 transfected in Tet-inducible HEK293-T-REx cells assessed as inhibition of channel current in presence of 780 uM intracellular Mg2+ by whole cell patch clamp analysis	ic50	0.0900	uM
3-[(2E)-3,7-dimethylocta-2,6-dienyl]-2,4-dihydroxy-6-pentylbenzoic acid	2035471: Inhibition of human TRPM7 transfected in HEK293 cells assessed as inhibition of channel current by whole cell patch clamp analysis	ic50	2.7000	uM

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Magnesium	decreases reaction, increases abundance, decreases abundance, affects cotreatment, affects response to substance	3
bisphenol A	decreases expression, increases expression, affects cotreatment	2
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, decreases expression	2
bisphenol F	affects cotreatment, decreases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases abundance, affects cotreatment, increases oxidation	1
methylparaben	increases expression	1
potassium chromate(VI)	decreases expression	1
1-nitropyrene	increases expression	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
glycidamide	increases expression	1
perfluorooctane sulfonic acid	decreases expression	1
U 0126	decreases reaction, affects reaction, decreases expression	1
K 7174	increases expression	1
(R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine	affects reaction, increases activity	1
bisphenol S	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Sunitinib	increases expression	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Cadmium	increases activity, increases expression, affects uptake	1
Calcium	decreases reaction, increases abundance	1
Calcium, Dietary	affects cotreatment, affects response to substance	1
Dexamethasone	affects cotreatment, decreases expression	1
Diuron	decreases expression	1
Doxorubicin	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Glucose	increases activity, increases expression, affects reaction, decreases expression, decreases reaction	1
Hydrogen Peroxide	affects cotreatment, increases expression	1
Indomethacin	affects cotreatment, decreases expression	1

ChEMBL screening assays

34 unique, capped per target: 34 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1252891	Binding	Induction of TRPM7 S-nitrosylation in HEK cells assessed as increase in Ca2+ level from extracellular space at 30 uM	Nitric oxide activates TRP channels by cysteine S-nitrosylation. — Nat Chem Biol

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2JS	Abcam HeLa TRPM7 KO	Cancer cell line	Female
CVCL_D8D6	Ubigene A-549 TRPM7 KO	Cancer cell line	Male
CVCL_E0SB	Ubigene HeLa TRPM7 KO	Cancer cell line	Female
CVCL_TU87	HAP1 TRPM7 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

33 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00282620	PHASE4	UNKNOWN	Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient’s Quality of Life.
NCT00603499	PHASE4	COMPLETED	Magnesium and Metabolic Syndrome
NCT00994006	PHASE4	COMPLETED	The Absorption of Magnesium Oxide Compared to Citrate in Healthy Subjects
NCT03088852	PHASE4	RECRUITING	Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
NCT03812380	PHASE3	TERMINATED	Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate
NCT05998863	PHASE3	RECRUITING	EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
NCT04675073	PHASE3	UNKNOWN	Preventive VT Substrate Ablation in Ischemic Heart Disease
NCT02216877	PHASE1/PHASE2	COMPLETED	Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease
NCT04382157	PHASE1/PHASE2	UNKNOWN	Magnesium Replacement and Hyperglycemia After Kidney Transplantation
NCT01700998	Not specified	COMPLETED	Magnesium Replacement Therapy to Prevent Acute Renal Failure in Critically Ill Patients
NCT02690012	Not specified	COMPLETED	Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies
NCT03976440	Not specified	UNKNOWN	Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
NCT04351451	Not specified	COMPLETED	Hypomagnesemia and Hypocalcemia Association Following Thyroidectomy
NCT04426994	Not specified	COMPLETED	Hypomagnesemia Associated With Proton-Pump Inhibitor Use
NCT06353750	Not specified	UNKNOWN	Intracellular Magnesium and Heart Failure
NCT06855550	Not specified	COMPLETED	Postoperative Incidence of Atrial Fibrillation Following Cardiac Surgery
NCT07056283	Not specified	RECRUITING	The Study of Urinary Biomarkers in Patients With Hypomagnesemia
NCT07089004	Not specified	COMPLETED	Hypomagnesemia and Its Clinical Outcome
NCT07380542	Not specified	COMPLETED	Dynamic Magnesium Replacement Strategies and 28-Day Mortality in Non-Cardiac Critically Ill Patients With Hypomagnesemia: A Target Trial Emulation
NCT07576621	Not specified	COMPLETED	Association Between Hypomagnesemia and Coagulopathy in Sepsis
NCT04189822	Not specified	ENROLLING_BY_INVITATION	Hearts in Rhythm Organization (HiRO)National Registry and Bio Bank
NCT04246450	Not specified	UNKNOWN	Arrhythmic Risk Stratification in Nonischemic Dilated Cardiomyopathy
NCT04548804	Not specified	UNKNOWN	Better Mechanistic Understanding of and Risk Stratification for Ventricular Tachyarrhythmias Through ECGI
NCT04599439	Not specified	UNKNOWN	CMR Based Prediction of Ventricular Tachycardia Events in Healed Myocardial Infarction (DEVELOP-VT)
NCT05799833	Not specified	UNKNOWN	Low QRS Voltages in Young Healthy Individuals and Athletes
NCT06321900	Not specified	UNKNOWN	Personalized Risk Prediction of Sudden Cardiac Death
NCT06739239	Not specified	RECRUITING	French COhoRte Extra-Vascular Implantable CardiovErter DefibrillatoR
NCT06763549	Not specified	ENROLLING_BY_INVITATION	COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
NCT06804499	Not specified	RECRUITING	Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study
NCT06888271	Not specified	NOT_YET_RECRUITING	DNA Methylation in Brugada Syndrome and Risk of Sudden Cardiac Death
NCT07436962	Not specified	RECRUITING	Loop Recorder Implantation in Patients With Mitral Annular Disjunction
NCT07545512	Not specified	NOT_YET_RECRUITING	ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
NCT06065852	Not specified	RECRUITING	National Registry of Rare Kidney Diseases